Form 4: Director Sells ESTA Shares Under 10b5-1 Plan

Establishment Labs Holdings Director Juan Jose Chacon Quiros reported sales of common shares totaling 33,925 units and a transfer of 179,240 shares to Sariel Group Ltd.

Summary

• Director Juan Jose Chacon Quiros, a director of Establishment Labs Holdings Inc. (ESTA), reported transactions on March 23, 2026.
• Transferred 179,240 common shares from direct holdings to Sariel Group Ltd. in an exempt transaction pursuant to Rule 16a-13.
• Acquired indirect beneficial ownership of 179,240 common shares through Sariel Group Ltd., over which the reporting person retains voting and dispositive power.
• Sold a total of 33,925 common shares (comprising 31,425, 787, 1,513, and 200 shares) at weighted average prices ranging from $60.232 to $63.01.
• These sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, direct beneficial ownership stands at 45,193 common shares, and indirect beneficial ownership through Sariel Group Ltd. is 1,223,579 common shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the director's sale of shares, although the impact is mitigated by the use of a Rule 10b5-1 plan, suggesting a pre-planned transaction rather than a reaction to new negative information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-arranged, non-discretionary sale, which can mitigate concerns about insider selling based on non-public information.

Negatives

• A director selling a significant number of shares (33,925 shares) could be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is often scrutinized by investors in the medical technology and aesthetics industry, as it can sometimes precede periods of underperformance or reflect personal financial planning unrelated to company prospects. However, the pre-arranged nature of 10b5-1 plans typically reduces the immediate negative signal compared to open market discretionary sales.

Related Party Transactions

• Transfer of 179,240 common shares from Juan Jose Chacon Quiros's direct holdings to Sariel Group Ltd.
• Juan Jose Chacon Quiros is a shareholder of Sariel Group Ltd. and retains voting and dispositive power over the shares held by Sariel Group Ltd., indicating a related party relationship.

Stakeholder Impact

• Shareholders: May interpret the director's sales as a negative signal, potentially leading to short-term price volatility, though the 10b5-1 plan context may temper concerns.

Key Dates

Recommendation

While the director's sale of shares could be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned financial management decision rather than a reaction to adverse company-specific news. The overall impact on the company's fundamentals is likely neutral, warranting a 'hold' recommendation for existing investors to observe future developments.

Keywords

Establishment Labs Holdings, ESTA, Form 4, Insider Trading, Director Sales, Juan Jose Chacon Quiros, 10b5-1 Plan, Share Transfer, Beneficial Ownership